Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECT 3 asthma Digihaler trial
NL-OMON53851Phase 4Withdrawn
- Sponsor
- PRA Health Sciences
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide + formoterol in asthma (2 arms), sponsored by PRA Health Sciences. Primary endpoint: Asthma control responder rate at Week 24. Planned start Dec 2022; status: withdrawn.
02
Drugs
budesonide + formoterol
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON53851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53851.